Delivery Order SPE2DB22D1106-SPE2DB25FFBN5
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,178.96 to AmerisourceBergen Drug Corp for 30 tablets of Xcopri 150 mg, with an ultimate completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the prime contractor. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $2,794.23 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 150 mg tablets, with a completion date of September 11, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Xcopri 200 mg tablets (30-count units) on May 20, 2025, with an ultimate completion date of May 21, 2025. This firm fixed-price delivery order, valued at $1,768.44, represents a non-set-aside competitive award and will be performed at the contractor's Conshohocken, Pennsylvania facility. The contract is issued as a child order under AmerisourceBergen's larger pharmaceutical supply vehicle...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for the supply of Xcopri 200 mg tablets (30-count units) with a contract value of $1,012.37. This is a firm fixed-price delivery order with an ultimate completion date of June 6, 2025, representing a short-duration pharmaceutical supply transaction. The contract is non-competitive and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on August 22, 2025, for the supply of Xcopri 200 mg tablets in quantities of 30 tablets. The contract, valued at $1,879.85 with a firm fixed price structure, represents a competitive award with no set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 25, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,652.69 to AmerisourceBergen Drug Corp for 30-tablet units of Xcopri 200 mg tablets, with performance completion targeted for August 20, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Xcopri 100 mg tablets in quantities of 30 units, with a ceiling value of $2,357.92 and an ultimate completion date of August 11, 2025. This competitively awarded, non-set-aside contract utilized firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance...
- The Defense Logistics Agency awarded a $3,927.06 delivery order to AmerisourceBergen Drug Corp for Xcopri 200 mg tablets (30-count units) on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside contract is structured as a firm fixed price delivery order to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Xcopri is a prescription anticonvulsant medication used in epilepsy treatment, reflecting the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $6,221.54 to AmerisourceBergen Drug Corp for the supply of Xcopri 100 mg tablets (30-count packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Xcopri 100 mg tablets (30-count packaging) valued at $1,037.97. This firm fixed-price delivery order, with an ultimate completion date of August 18, 2025, represents a competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFBN5Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,522.20 to AmerisourceBergen Drug Corp for 30-tablet supplies of Xcopri 200 mg tablets. The award, made on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed price, competitively awarded delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a prime contractor for pharmaceutical and medical supply distribution to federal healthcare systems, particularly supporting military and veteran healthcare needs. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999.999 billion through December 2026. This prime vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies globally to support military healthcare programs. The contract supports critical federal healthcare operations including the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with Xcopri (eslicarbazepine acetate) being a neurological medication delivered under this framework to fulfill ongoing federal medical procurement requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.5k | 8/5/25 |